George Farmer
Stock Analyst at Scotiabank
(1.82)
# 3,186
Out of 4,918 analysts
69
Total ratings
36.59%
Success rate
-9.12%
Average return
Main Sectors:
Top Industries:
Stocks Rated by George Farmer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ACLX Arcellx | Maintains: Sector Outperform | $93 → $133 | $72.08 | +84.52% | 3 | Jul 31, 2025 | |
| INMB INmune Bio | Downgrades: Sector Underperform | $23 → $0.6 | $2.86 | -78.98% | 3 | Jul 1, 2025 | |
| URGN UroGen Pharma | Maintains: Sector Outperform | $23 → $47 | $19.88 | +136.42% | 1 | Jun 13, 2025 | |
| SNDX Syndax Pharmaceuticals | Maintains: Sector Perform | $16 → $17 | $10.38 | +63.78% | 4 | May 6, 2025 | |
| TARA Protara Therapeutics | Initiates: Sector Outperform | $12 | $3.16 | +279.75% | 1 | Apr 16, 2025 | |
| TPST Tempest Therapeutics | Downgrades: Sector Perform | $91 → $9 | $7.46 | +20.64% | 4 | Apr 10, 2025 | |
| ADAP Adaptimmune Therapeutics | Maintains: Sector Outperform | $3.15 → $1.4 | $0.08 | +1,665.45% | 2 | Mar 21, 2025 | |
| JANX Janux Therapeutics | Maintains: Sector Perform | $62 → $41 | $23.98 | +70.98% | 4 | Feb 28, 2025 | |
| NAMS NewAmsterdam Pharma Company | Maintains: Sector Outperform | $47 → $52 | $21.66 | +140.07% | 4 | Feb 27, 2025 | |
| BMRN BioMarin Pharmaceutical | Maintains: Sector Perform | $78 → $80 | $60.31 | +32.65% | 8 | Feb 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $244 → $224 | $132.20 | +69.44% | 3 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $102 | $33.98 | +200.18% | 1 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $18 → $10 | $6.32 | +58.23% | 2 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Sector Outperform | $439 → $715 | $690.32 | +3.58% | 5 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $20 → $23 | $6.59 | +249.01% | 2 | Oct 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $20 | $3.63 | +450.96% | 1 | Sep 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $21 → $41 | $1.61 | +2,446.58% | 3 | Sep 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $70 → $76 | $38.45 | +97.66% | 4 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $13 | $2.99 | +334.78% | 1 | Mar 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $109 | $27.64 | +294.36% | 3 | Nov 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $94 → $87 | $78.04 | +11.48% | 5 | Nov 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $33 | $2.10 | +1,471.43% | 1 | Oct 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $0.98 | +3,989.14% | 1 | Jul 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $20 → $27 | $36.81 | -26.65% | 3 | May 6, 2020 |
Arcellx
Jul 31, 2025
Maintains: Sector Outperform
Price Target: $93 → $133
Current: $72.08
Upside: +84.52%
INmune Bio
Jul 1, 2025
Downgrades: Sector Underperform
Price Target: $23 → $0.6
Current: $2.86
Upside: -78.98%
UroGen Pharma
Jun 13, 2025
Maintains: Sector Outperform
Price Target: $23 → $47
Current: $19.88
Upside: +136.42%
Syndax Pharmaceuticals
May 6, 2025
Maintains: Sector Perform
Price Target: $16 → $17
Current: $10.38
Upside: +63.78%
Protara Therapeutics
Apr 16, 2025
Initiates: Sector Outperform
Price Target: $12
Current: $3.16
Upside: +279.75%
Tempest Therapeutics
Apr 10, 2025
Downgrades: Sector Perform
Price Target: $91 → $9
Current: $7.46
Upside: +20.64%
Adaptimmune Therapeutics
Mar 21, 2025
Maintains: Sector Outperform
Price Target: $3.15 → $1.4
Current: $0.08
Upside: +1,665.45%
Janux Therapeutics
Feb 28, 2025
Maintains: Sector Perform
Price Target: $62 → $41
Current: $23.98
Upside: +70.98%
NewAmsterdam Pharma Company
Feb 27, 2025
Maintains: Sector Outperform
Price Target: $47 → $52
Current: $21.66
Upside: +140.07%
BioMarin Pharmaceutical
Feb 20, 2025
Maintains: Sector Perform
Price Target: $78 → $80
Current: $60.31
Upside: +32.65%
Feb 13, 2025
Maintains: Sector Outperform
Price Target: $244 → $224
Current: $132.20
Upside: +69.44%
Feb 13, 2025
Initiates: Sector Outperform
Price Target: $102
Current: $33.98
Upside: +200.18%
Jan 8, 2025
Maintains: Sector Perform
Price Target: $18 → $10
Current: $6.32
Upside: +58.23%
Nov 5, 2024
Upgrades: Sector Outperform
Price Target: $439 → $715
Current: $690.32
Upside: +3.58%
Oct 18, 2024
Maintains: Sector Outperform
Price Target: $20 → $23
Current: $6.59
Upside: +249.01%
Sep 30, 2024
Initiates: Sector Outperform
Price Target: $20
Current: $3.63
Upside: +450.96%
Sep 27, 2024
Maintains: Sector Outperform
Price Target: $21 → $41
Current: $1.61
Upside: +2,446.58%
Aug 12, 2024
Maintains: Sector Outperform
Price Target: $70 → $76
Current: $38.45
Upside: +97.66%
Mar 14, 2024
Initiates: Sector Outperform
Price Target: $13
Current: $2.99
Upside: +334.78%
Nov 17, 2020
Downgrades: Market Perform
Price Target: $109
Current: $27.64
Upside: +294.36%
Nov 6, 2020
Maintains: Market Perform
Price Target: $94 → $87
Current: $78.04
Upside: +11.48%
Oct 27, 2020
Initiates: Outperform
Price Target: $33
Current: $2.10
Upside: +1,471.43%
Jul 20, 2020
Initiates: Outperform
Price Target: $40
Current: $0.98
Upside: +3,989.14%
May 6, 2020
Maintains: Market Perform
Price Target: $20 → $27
Current: $36.81
Upside: -26.65%